Conference Paper

Point-of-care monitoring and diagnostics for autoimmune diseases.

Dept. of Comput. Sci., Univ. of Ioannina, Ioannina
DOI: 10.1109/BIBE.2008.4696778 Conference: Proceedings of the 8th IEEE International Conference on Bioinformatics and Bioengineering, BIBE 2008, October 8-10, 2008, Athens, Greece
Source: DBLP

ABSTRACT In this paper we present the POCEMON platform, a platform aiming to the early prognosis and diagnosis of autoimmune diseases at any point of care, even the primary. The objective of the POCEMON platform is the development of a diagnostic lab-on-chip device based on genomic microarrays of HLA-typing. The POCEMON is going to advance and promote the primary health care across Europe by supporting a) point-of-care diagnostics, b) monitoring of immune system status and c) management of the chronic multiple sclerosis (MS) and rheumatoid arthritis (RA) autoimmune diseases. The platform combines high-end Information and Communication Technologies based on microfluidics, microelectronics, microarrays and intelligent diagnosis algorithms.

1 Bookmark
 · 
144 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The developing world does not have access to many of the best medical diagnostic technologies; they were designed for air-conditioned laboratories, refrigerated storage of chemicals, a constant supply of calibrators and reagents, stable electrical power, highly trained personnel and rapid transportation of samples. Microfluidic systems allow miniaturization and integration of complex functions, which could move sophisticated diagnostic tools out of the developed-world laboratory. These systems must be inexpensive, but also accurate, reliable, rugged and well suited to the medical and social contexts of the developing world.
    Nature 08/2006; 442(7101):412-8. · 38.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The systematic study of multiple sclerosis (MS) in populations, started in 1929 by Sydney Allison, now consists of over 400 publications dealing with the prevalence of MS throughout the world. However, any attempt to redefine the pattern of geographical differences in MS frequency remains as difficult as ever. The comparison of prevalence studies carried out in different areas and times is made difficult by the variability in surveyed population sizes, age structures, ethnic origins and composition, and the difficult quantification of numerators, especially regarding the recognition of benign and very early cases. Additionally, complete case ascertainment depends on access to medical care, local medical expertise, number of neurologists, accessibility and availability of new diagnostic procedures, the degree of public awareness about MS, and the investigators' zeal and resources. Critical examination of the more recent data on MS prevalence leads to some revisions of previously held concepts, the most interesting of which is the appreciation of the greater influence of genetic factors on disease acquisition. The rarity of MS among Samis, Turkmen, Uzbeks, Kazakhs, Kyrgyzis, native Siberians, North and South Amerindians, Chinese, Japanese, African blacks and New Zealand Maoris, as well as the high risk among Sardinians, Parsis and Palestinians, clearly indicate that the different susceptibilities of distinct racial and ethnic groups are an important determinant of the uneven geographic distribution of the disease. The updated distribution of MS in Europe, showing many exceptions to the previously described north-south gradient, requires more explanation than simply a prevalence-latitude relationship. Prevalence data imply that racial and ethnic differences are important in influencing the worldwide distribution of MS and that its geography must be interpreted in terms of the probable discontinuous distribution of genetic susceptibility alleles, which can however be modified by environment. Because the environmental and genetic determinants of geographic gradients are by no means mutually exclusive, the race versus place controversy is, to some extent, a useless and sterile debate.
    Neurological Sciences 05/2001; 22(2):117-39. · 1.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Accurate diagnosis of rheumatoid arthritis may be difficult early in its course and demands high clinical suspicion, astute examination, and appropriate investigations. Early use of disease-modifying antirheu- matic drugs and biologics has improved outcomes but requires close monitoring of disease course and adverse events. © 2007 Elsevier Inc. All rights reserved.
    Clinical symposia (Summit, N.J.: 1957) 02/1986; 38(2):1-32.

Full-text (6 Sources)

Download
30 Downloads
Available from
May 31, 2014